#USA #New York #Class Action #Gross Law Firm #Unicycive Therapeutics

Class Action Lawsuit Against Unicycive Therapeutics

On October 9, 2025, The Gross Law Firm announced the filing of a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that seeks to recover losses for shareholders who purchased shares during a specified period. This legal action highlights serious allegations regarding the integrity of statements made by the company pertaining to its operational readiness and regulatory compliance with the FDA.

Allegations Against Unicycive

The complaint against Unicycive asserts that throughout the class period, which extends from March 29, 2024, to June 27, 2025, the company's executives made materially false or misleading statements. The lawsuit details the following key allegations:

1. Overstated Manufacturing Compliance: The company allegedly overstated its readiness and ability to meet the FDA's manufacturing compliance requirements. This claim raises concerns about the adequacy of their production processes and the impact on the safety and effectiveness of their products.

2. Exaggerated Regulatory Prospects: The regulatory prospects for Unicycive's oxylanthanum carbonate new drug application were reportedly overstated. This allegation suggests that the company misled investors about the likelihood of successful FDA approval for its drug, potentially inflating stock prices based on unsupported claims.

3. Misleading Public Statements: As a result of these issues, public statements made by the company were found to be materially false and misleading at all relevant times, raising questions about the management's transparency and reliability.

Important Information for Shareholders

Shareholders who believe they have been affected by these actions are advised to register for the class action promptly, as the deadline to seek appointment as a lead plaintiff is October 14, 2025. By registering, investors will receive periodic updates regarding the case's progress via portfolio monitoring software.

The Gross Law Firm has emphasized that appointment as a lead plaintiff is not a prerequisite for participants to seek recovery. Additionally, participation in the case carries no cost or obligation for the shareholders.

Why Choose The Gross Law Firm?

The Gross Law Firm, known nationally for its active role in protecting investor rights, aims to assist individuals who have suffered losses due to deceptive business practices. The firm is dedicated to holding companies accountable for dishonesty, ensuring that investors can seek justice and recover their losses when they have been misled by corporations.

The law firm argues that companies must engage in responsible business practices and promote good corporate citizenship. Unicycive shareholders are encouraged to reach out and participate in this class action to hold the company accountable and potentially recover their financial losses.

Contact Information

To inquire further, investors can reach The Gross Law Firm at:

Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

The Gross Law Firm urges affected shareholders to take action and not to miss the opportunity for a potential recovery from their investments in Unicycive Therapeutics. By working together, investors can ensure that corporations prioritize transparency and uphold their responsibilities to shareholders.

Conclusion

As the situation unfolds, it's essential for shareholders to stay informed and connected. Engaging with legal counsel and participating in this class action can empower investors and potentially recover losses incurred as a result of misleading practices by Unicycive Therapeutics.